Literature DB >> 18177838

Pharmacokinetics and selectivity of porphyrin synthesis after topical application of hexaminolevulinate in patients with cervical intraepithelial neoplasia.

Peter Hillemanns1, Xiuli Wang, Hermann Hertel, Vaagn Andikyan, Marija Hillemanns, Herbert Stepp, Philipp Soergel.   

Abstract

OBJECTIVE: Photodynamic therapy has the potential of a minimal invasive outpatient procedure for CIN patients at reproductive ages. The purpose of this study was to examine the pharmacokinetics and selectivity of porphyrin synthesis after topical application of hexaminolevulinate (HAL) in patients with cervical intraepithelial neoplasia (CIN). STUDY
DESIGN: Twenty-four women with CIN 1-3 received 4 mmol/L or 10 mmol/L HAL dissolved in thermolabile pluronic F 127 gel topically 5-720 minutes before surgical conization. The microscopic fluorescence pattern was quantified by ex vivo fluorescence spectroscopy at a wavelength of 635 nm and semiquantitatively by digital image analysis from cryosections.
RESULTS: With 4 and 10 mmol/L HAL, porphyrin fluorescence intensity increased over time, reaching a peak after 180-540 minutes application intervals in CIN and normal epithelium. However, the peak was much more pronounced in CIN than in normal tissues. The fluorescence intensity with 10 mmol/L was significantly higher than that with 4 mmol/L in CIN tissues (P < .05). Maximum intensity could generally be detected in the lower layer of the epithelium.
CONCLUSION: HAL seems to be a promising molecule for fluorescence diagnosis. For further treatment studies, we recommend application of 10 mmol/L HAL 300-540 minutes before photodynamic therapy in CIN.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18177838     DOI: 10.1016/j.ajog.2007.07.045

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  6 in total

1.  Multicentre, prospective, randomised controlled trial to evaluate hexaminolevulinate photodynamic therapy (Cevira) as a novel treatment in patients with high-grade squamous intraepithelial lesion: APRICITY phase 3 study protocol.

Authors:  Fei Chen; Zoltán Novák; Christian Dannecker; Ctirad Mokráš; Long Sui; Youzhong Zhang; Zhixue You; Ling Han; Jinghe Lang; Peter Hillemanns
Journal:  BMJ Open       Date:  2022-06-06       Impact factor: 3.006

Review 2.  Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions.

Authors:  Demian van Straten; Vida Mashayekhi; Henriette S de Bruijn; Sabrina Oliveira; Dominic J Robinson
Journal:  Cancers (Basel)       Date:  2017-02-18       Impact factor: 6.639

3.  5-Aminolevulinic Acid-Squalene Nanoassemblies for Tumor Photodetection and Therapy: In Vitro Studies.

Authors:  Andrej Babič; V Herceg; E Bastien; H-P Lassalle; L Bezdetnaya; Norbert Lange
Journal:  Nanoscale Res Lett       Date:  2018-01-11       Impact factor: 4.703

4.  Efficacy of commercially available biological agents for the topical treatment of cervical intraepithelial neoplasia: a systematic review.

Authors:  Alex Baleka Mutombo; Cindy Simoens; Rahma Tozin; Johannes Bogers; Jean-Pierre Van Geertruyden; Yves Jacquemyn
Journal:  Syst Rev       Date:  2019-06-07

5.  Photodynamic therapy for gynecological diseases and breast cancer.

Authors:  Natashis Shishkova; Olga Kuznetsova; Temirbolat Berezov
Journal:  Cancer Biol Med       Date:  2012-03       Impact factor: 4.248

6.  Bioadhesive mini-tablets for vaginal drug delivery.

Authors:  Marianne Hiorth; Susanne Nilsen; Ingunn Tho
Journal:  Pharmaceutics       Date:  2014-08-27       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.